AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Advanced Breast Cancer
Interventions: DRUG: AZD2171|DRUG: Fulvestrant
Sponsor: AstraZeneca